Jenburkt Pharmaceuticals Ltd Stock Price Today (NSE: JENBURPH)
Fundamental Score
Jenburkt Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Jenburkt Pharmaceuticals Ltd share price today is ₹1064.60, up +0.00% on NSE/BSE as of 17 February 2026. Jenburkt Pharmaceuticals Ltd (JENBURPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹506.05 (Cr). The 52-week high for JENBURPH share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 15.33x, JENBURPH is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 19.87% and a debt-to-equity ratio of 0.01.
Jenburkt Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Jenburkt Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Jenburkt Pharmaceuticals Share Price: A Financial Stability Analysis
The pharmaceutical industry, known for its high R&D expenditure and regulatory hurdles, often sees fluctuations in stock performance driven by clinical trial outcomes and patent expirations. This analysis examines the financial stability of Jenburkt Pharmaceuticals, focusing on its current market valuation. Currently, the Jenburkt Pharmaceuticals share price stands at ₹1063.849976. A key metric for initial assessment is the Price-to-Earnings (PE) ratio, which for Jenburkt Pharmaceuticals is 15.33.
This PE ratio provides a relative valuation compared to its sector peers. For example, considering
Mankind Pharma Ltd, differences in management quality can significantly influence investor perception and, consequently, the PE ratio. A company perceived as having stronger leadership, better strategic vision, or a more robust pipeline, like Mankind Pharma Ltd, might command a higher PE ratio than Jenburkt Pharmaceuticals, even with similar financial performance. This difference doesn't automatically indicate undervaluation or overvaluation, but it highlights potential areas for further investigation into management's effectiveness and future growth prospects.A significant strength of Jenburkt Pharmaceuticals is its Return on Capital Employed (ROCE) of 27.18%. This robust ROCE illustrates the company's efficiency in generating profits from its capital investments. A high ROCE like this contributes significantly to the company's economic moat. The ability to consistently generate high returns on invested capital makes it difficult for competitors to erode Jenburkt's profitability. It indicates a competitive advantage, whether through proprietary formulations, efficient manufacturing processes, or strong brand recognition.
This analysis forms a component of a comprehensive 80-parameter fundamental audit, overseen and verified by Sweta Mishra. It's important to note that this is an observational analysis of publicly available data and does not constitute financial advice. The information presented here is intended for informational purposes only.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Jenburkt Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of JENBURPH across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (19.87%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.18%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (22.75%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 15.33 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Excellent EPS Growth (17.09% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (16.18% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (105.25x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹53.78 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Limited Growth History (4.99% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Limited Institutional Interest (FII+DII: 0.12%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Jenburkt Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Jenburkt Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About JENBURPH (Jenburkt Pharmaceuticals Ltd)
Jenburkt Pharmaceuticals Ltd (JENBURPH) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹506.05 (Cr). Jenburkt Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 19.87% and a ROCE of 27.18%. The debt-to-equity ratio stands at 0.01, reflecting the company's capital structure. Investors tracking JENBURPH share price can monitor key metrics including P/E ratio, promoter holding of 46.66%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
JENBURPH Share Price: Frequently Asked Questions
What is the current share price of Jenburkt Pharmaceuticals Ltd (JENBURPH)?
As of 17 Feb 2026, 10:13 am IST, Jenburkt Pharmaceuticals Ltd share price is ₹1064.60. The JENBURPH stock has a market capitalisation of ₹506.05 (Cr) on NSE/BSE.
Is JENBURPH share price Overvalued or Undervalued?
JENBURPH share price is currently trading at a P/E ratio of 15.33x, compared to the industry average of 31.77x. Based on this relative valuation, the Jenburkt Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of JENBURPH share price?
The 52-week high of JENBURPH share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Jenburkt Pharmaceuticals Ltd share price?
Key factors influencing JENBURPH share price include quarterly earnings growth (Sales Growth: 10.53%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Jenburkt Pharmaceuticals Ltd a good stock for long-term investment?
Jenburkt Pharmaceuticals Ltd shows a 5-year Profit Growth of 16.18% and an ROE of 19.87%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing in JENBURPH shares.
How does Jenburkt Pharmaceuticals Ltd compare with its industry peers?
Jenburkt Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare JENBURPH share price P/E of 15.33x and ROE of 19.87% against the industry averages to determine competitive standing.
What is the P/E ratio of JENBURPH and what does it mean?
JENBURPH share price has a P/E ratio of 15.33x compared to the industry average of 31.77x. Investors pay ₹15 for every ₹1 of annual earnings.
How is JENBURPH performing according to Bull Run's analysis?
JENBURPH has a Bull Run fundamental score of 63.3/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does JENBURPH belong to?
JENBURPH operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Jenburkt Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for JENBURPH?
JENBURPH has an ROE of 19.87%, which indicates excellent management efficiency. ROE measures how efficiently Jenburkt Pharmaceuticals Ltd generates profits from shareholders capital.
How is JENBURPH debt-to-equity ratio and what does it indicate?
JENBURPH has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk.
What is JENBURPH dividend yield and is it a good dividend stock?
JENBURPH offers a dividend yield of 1.57%, meaning you receive ₹1.57 annual dividend for every ₹100 invested in Jenburkt Pharmaceuticals Ltd shares.
How has JENBURPH share price grown over the past 5 years?
JENBURPH has achieved 5-year growth rates of: Sales Growth 4.99%, Profit Growth 16.18%, and EPS Growth 17.09%.
What is the promoter holding in JENBURPH and why does it matter?
Promoters hold 46.66% of JENBURPH shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Jenburkt Pharmaceuticals Ltd.
What is JENBURPH market capitalisation category?
JENBURPH has a market capitalisation of ₹506 crores, placing it in the Small-cap category.
How volatile is JENBURPH stock?
JENBURPH has a beta of N/A. A beta > 1 suggests the Jenburkt Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is JENBURPH operating profit margin trend?
JENBURPH has a 5-year average Operating Profit Margin (OPM) of 22.75%, indicating the company's operational efficiency.
How is JENBURPH quarterly performance?
Recent quarterly performance shows Jenburkt Pharmaceuticals Ltd YoY Sales Growth of 10.53% and YoY Profit Growth of 5.83%.
What is the institutional holding pattern in JENBURPH?
JENBURPH has FII holding of 0.00% and DII holding of 0.12%. Significant institutional holding often suggests professional confidence in the Jenburkt Pharmaceuticals Ltd stock.